^
Association details:
| Biomarker: | EGFR wild-type + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).
Published date:
05/26/2022
Excerpt:
Overall, objective response rate (ORR) was 41.7% (95% CI: 22.1, 63.4)….Tepotinib showed meaningful activity, especially in first line, in the first trial of a MET inhibitor in EGFR WT NSCLC with high-level METamp to enroll based on a convenient LBx assay.
DOI:
10.1200/JCO.2022.40.16_suppl.9121
Trial ID:
Test:
